远处转移性口咽鳞状细胞癌的原发部位手术
基于美国国家癌症数据库的回顾性人群队列研究,纳入2010至2015年627例新诊断远处转移性口咽鳞状细胞癌且初始治疗含全身化疗的患者;多变量分析显示局部放疗与总生存改善独立相关(OR 0.64,CI [0.51-0.81]),局部手术与总生存无独立相关(OR 0.99,CI [0.65-1.53])。
要点
- 局部放疗联合全身治疗与总生存改善独立相关(OR 0.64,CI [0.51-0.81])。
- 局部手术联合全身治疗与总生存无独立相关(OR 0.99,CI [0.65-1.53])。
- 全队列及HPV阳性患者中放疗联合全身治疗生存最佳,单纯全身治疗最差。
核心结论
- 在远处转移性口咽鳞状细胞癌患者中,全身治疗基础上加用根治剂量局部放疗与总生存改善相关,优于单纯全身治疗。
- 在该人群中,全身治疗基础上加用局部手术未见显著生存获益,与HPV状态无关。
研究设计与样本
- 美国国家癌症数据库的回顾性人群队列研究,纳入2010至2015年新诊断远处转移性口咽鳞状细胞癌且初始治疗含全身化疗的患者627例。
- 比较单纯全身治疗与联合局部手术或根治剂量放疗的总生存,并控制多种临床人口学因素。
主要发现
- 局部放疗与总生存改善独立相关(OR 0.64,CI [0.51-0.81])。
- 局部手术与总生存无独立相关(OR 0.99,CI [0.65-1.53])。
- 较晚T分期与较差总生存相关:T3 vs T1 的 OR 1.69(CI [1.14-2.50]),T4 vs T1 的 OR 1.77(CI [1.22-2.58])。
- HPV阳性肿瘤与HPV阴性相比总生存改善(OR 0.79,CI [0.64-0.97]);多药化疗与单药化疗相比总生存改善(OR 0.78,CI [0.62-1.00])。
- 全队列及HPV阳性患者中放疗联合全身治疗生存最佳,单纯全身治疗最差。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Determine if intensive local therapy (i.e., local surgery or radiation) has a survival benefit for patients presenting with distantly metastatic oropharyngeal squamous cell carcinoma (OPSCC). METHODS: Retrospective population-based cohort study of patients in the National Cancer Database presenting with distantly metastatic OPSCC. Overall survival (OS) was compared for patients receiving systemic therapy alone or in combination with local surgery or curative dose radiation, controlling for various clinicodemographic factors. RESULTS: Between 2010 and 2015, 627 patients presented with newly diagnosed, metastatic OPSCC and an initial treatment course including systemic chemotherapy. Multivariable analysis demonstrated that local radiation therapy was independently associated with improved OS (OR 0.64, CI [0.51-0.81]); local surgery was not independently associated with improved OS (OR 0.99, CI [0.65-1.53]). Higher T stages were associated with worse OS (OR 1.69, CI [1.14-2.50] for T3 and OR 1.77, CI [1.22-2.58] for T4 compared to T1). HPV-positive (HPV+) tumors were associated with improved OS compared to HPV- (OR 0.79, CI [0.64-0.97]). Multiagent chemotherapy was associated with improved OS compared to single-agent (OR 0.78, CI [0.62-1.00]). The best survival for the entire cohort and for HPV+ patients was for radiation with systemic therapy and the worst survival for systemic therapy alone. CONCLUSIONS: Curative dose local radiotherapy in addition to systemic therapy is associated with improved OS compared to systemic therapy alone in patients presenting with distantly metastatic OPSCC. There is not a significant survival benefit for local surgery in addition to systemic therapy in this patient population, regardless of HPV status. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:2243-2251, 2024.
引用
- Carey RM, Prasad A, Wei K, et al. Primary Site Surgery in Distantly Metastatic Oropharyngeal Squamous Cell Carcinoma. Laryngoscope. 2023. PMID: 37947342. doi:10.1002/lary.31177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。